

Treatment of muscleâ€invasive and advanced bladder c

Ca-A Cancer Journal for Clinicians

70, 404-423

DOI: [10.3322/caac.21631](https://doi.org/10.3322/caac.21631)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients' Omics Signatures. <i>Cancers</i> , 2020, 12, 3519.	1.7	12
2	Clinical Perspectives of ERCC1 in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8829.	1.8	6
3	Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer. <i>Cancers</i> , 2020, 12, 3776.	1.7	8
4	Hypomethylation of PlncRNA-1 promoter enhances bladder cancer progression through the miR-136-5p/Smad3 axis. <i>Cell Death and Disease</i> , 2020, 11, 1038.	2.7	25
6	Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 43-51.	3.2	125
7	Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer. <i>International Journal of Biological Sciences</i> , 2021, 17, 3255-3267.	2.6	15
8	Strategies to Get Drugs across Bladder Penetrating Barriers for Improving Bladder Cancer Therapy. <i>Pharmaceutics</i> , 2021, 13, 166.	2.0	17
9	NEAT1 as a competing endogenous RNA in tumorigenesis of various cancers: Role, mechanism and therapeutic potential. <i>International Journal of Biological Sciences</i> , 2021, 17, 3428-3440.	2.6	45
10	GM-CSF-Loaded Nanoparticles for Photothermal-Assisted Immunotherapy against Orthotopic Bladder Cancer. <i>Oncologie</i> , 2021, 23, 359-371.	0.2	5
11	C19orf10 promotes malignant behaviors of human bladder carcinoma cells via regulating the PI3K/AKT and Wnt/ $\beta$ -catenin pathways. <i>Journal of Cancer</i> , 2021, 12, 4341-4354.	1.2	6
12	circCEP128 Knockdown Suppresses Bladder Cancer Progression via Regulating microRNA-515-5p/SDC1 Axis. <i>Cancer Management and Research</i> , 2021, Volume 13, 2885-2896.	0.9	9
13	The Antitumor Effects of Plasma-Activated Saline on Muscle-Invasive Bladder Cancer Cells In Vitro and In Vivo Demonstrate Its Feasibility as a Potential Therapeutic Approach. <i>Cancers</i> , 2021, 13, 1042.	1.7	15
14	Exploration of a Robust and Prognostic Immune Related Gene Signature for Cervical Squamous Cell Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 625470.	1.6	11
15	Predictive biomarkers in bladder cancer. <i>Biomarkers in Medicine</i> , 2021, 15, 241-246.	0.6	2
17	FUT7 Promotes the Epithelial-Mesenchymal Transition and Immune Infiltration in Bladder Urothelial Carcinoma. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 1069-1084.	1.6	17
18	Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer. <i>BMC Cancer</i> , 2021, 21, 458.	1.1	14
19	Construction of an immune-related LncRNA signature with prognostic significance for bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4326-4339.	1.6	19
20	The Regulating Effect of Autophagy-Related MiRNAs in Kidney, Bladder, and Prostate Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-8.	0.6	5

#	ARTICLE	IF	CITATIONS
21	circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGF $\beta$ 2R1/VEGF-D signaling. <i>Molecular Therapy</i> , 2021, 29, 1838-1852.	3.7	45
22	HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4410-4421.	3.2	8
23	Identification of a prognostic signature based on immune-related genes in bladder cancer. <i>Genomics</i> , 2021, 113, 1203-1218.	1.3	5
24	Atlantis exploration: predictive biomarkers to immunotherapy response. <i>Onkourologiya</i> , 2021, 17, 167-177.	0.1	1
25	Treatment of advanced urogenital cancers with immune checkpoint inhibitors. <i>Journal of the Korean Medical Association</i> , 2021, 64, 349-357.	0.1	0
26	Sex Hormone Receptor Signaling in Bladder Cancer: A Potential Target for Enhancing the Efficacy of Conventional Non-Surgical Therapy. <i>Cells</i> , 2021, 10, 1169.	1.8	17
27	Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics. <i>Frontiers in Oncology</i> , 2021, 11, 672262.	1.3	11
28	Real World Outcomes of Patients with Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 597-612.	0.9	6
29	Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 701298.	1.3	9
30	Development of a Ferroptosis-Related lncRNA Signature to Predict the Prognosis and Immune Landscape of Bladder Cancer. <i>Disease Markers</i> , 2021, 2021, 1-22.	0.6	15
31	Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	2
32	Advanced micro/nanomotors for enhanced bioadhesion and tissue penetration. <i>Applied Materials Today</i> , 2021, 23, 101034.	2.3	21
33	Activation of the DDR Pathway Leads to the Down-Regulation of the TGF $\beta$ 2 Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 634741.	2.2	20
34	Detrimental Effect of Various Preparations of the Human Amniotic Membrane Homogenate on the 2D and 3D Bladder Cancer In vitro Models. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 690358.	2.0	6
35	The Roles of CircRNAs in Bladder Cancer: Biomarkers, Tumorigenesis Drivers, and Therapeutic Targets. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 666863.	1.8	11
36	Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7201.	1.8	8
37	Antitumor effects of hyperthermia with plasma-treated solutions on 3D bladder tumor spheroids. <i>Plasma Processes and Polymers</i> , 2021, 18, 2100070.	1.6	8
38	Y-Box Binding Protein 1 Regulates Angiogenesis in Bladder Cancer via miR-29b-3p-VEGFA Pathway. <i>Journal of Oncology</i> , 2021, 2021, 1-9.	0.6	7

#	ARTICLE	IF	CITATIONS
39	Bladder cancer: shedding light on the most promising investigational drugs in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 837-855.	1.9	14
40	Urothelial carcinoma in the era of immune checkpoint inhibitors. <i>Immunotherapy</i> , 2021, 13, 953-964.	1.0	5
41	Prognostic Value of the Systemic Inflammatory Response Index in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Population-Based Study. <i>Frontiers in Oncology</i> , 2021, 11, 722151.	1.3	8
42	GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 795-806.	2.0	7
43	Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. <i>Future Oncology</i> , 2021, 17, 3137-3150.	1.1	21
44	Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 643282.	2.2	17
45	An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer. <i>Nature Communications</i> , 2021, 12, 4906.	5.8	67
46	Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. <i>Cancers</i> , 2021, 13, 4411.	1.7	31
47	LINC01410 leads the migration, invasion and EMT of bladder cancer cells by modulating miR-4319 / Snail1. <i>Cancer Cell International</i> , 2021, 21, 429.	1.8	3
48	Basal and Luminal Molecular Subtypes in Naturally-Occurring Canine Urothelial Carcinoma are Associated with Tumor Immune Signatures and Dog Breed. <i>Bladder Cancer</i> , 2021, 7, 317-333.	0.2	3
49	Integrative Transcriptome Profiling Reveals SKA3 as a Novel Prognostic Marker in Non-Muscle Invasive Bladder Cancer. <i>Cancers</i> , 2021, 13, 4673.	1.7	5
50	Cancer derived exosomes induce macrophages immunosuppressive polarization to promote bladder cancer progression. <i>Cell Communication and Signaling</i> , 2021, 19, 93.	2.7	23
51	Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling. <i>Cancers</i> , 2021, 13, 4891.	1.7	21
52	LINC00265 promotes the viability, proliferation, and migration of bladder cancer cells via the miR-4677-3p/FGF6 axis. <i>Human and Experimental Toxicology</i> , 2021, 40, S434-S446.	1.1	6
53	Novel Mouse Models of Bladder Cancer Identify a Prognostic Signature Associated with Risk of Disease Progression. <i>Cancer Research</i> , 2021, 81, 5161-5175.	0.4	7
54	Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment. <i>Pharmaceutics</i> , 2021, 13, 1415.	2.0	10
55	Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9526.	1.8	8
56	Association Between Alcohol Consumption and Risk of Bladder Cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies. <i>Frontiers in Oncology</i> , 2021, 11, 696676.	1.3	10

#	ARTICLE	IF	CITATIONS
57	Calculated identification of mutator-derived lncRNA signatures of genomic instability to predict the clinical outcome of muscle-invasive bladder cancer. <i>Cancer Cell International</i> , 2021, 21, 476.	1.8	2
58	Bladder tumor ILC1s undergo Th17-like differentiation in human bladder cancer. <i>Cancer Medicine</i> , 2021, 10, 7101-7110.	1.3	5
59	Multislice Spiral Computed Tomography under Hybrid Iterative Reconstruction Algorithm in Staging Diagnosis of Bladder Cancer and Ceramide Glycosylation. <i>Scientific Programming</i> , 2021, 2021, 1-8.	0.5	0
60	Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 732.e9-732.e16.	0.8	6
61	Isorhapontigenin (ISO) inhibits EMT through FOXO3A/METTL14/VIMENTIN pathway in bladder cancer cells. <i>Cancer Letters</i> , 2021, 520, 400-408.	3.2	20
62	Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells. <i>International Journal of Biological Sciences</i> , 2021, 17, 3456-3475.	2.6	14
63	Complete Response With Immunotherapy: A Case of Metastatic Bladder Cancer. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2021, 9, 232470962110356.	0.3	0
64	CircRNAs: Emerging Bladder Cancer Biomarkers and Targets. <i>Frontiers in Oncology</i> , 2020, 10, 606485.	1.3	7
65	A three dimensional computer model of urothelium and bladder cancer initiation, progress and collective invasion. <i>Informatics in Medicine Unlocked</i> , 2021, 26, 100750.	1.9	0
66	N6-methyladenosine-related non-coding RNAs are potential prognostic and immunotherapeutic responsiveness biomarkers for bladder cancer. <i>EPMA Journal</i> , 2021, 12, 589-604.	3.3	18
67	Prognostic value of immune-related lncRNA pairs in patients with bladder cancer. <i>World Journal of Surgical Oncology</i> , 2021, 19, 304.	0.8	2
68	Identification of a Novel Pyroptosis-Related Gene Signature for Predicting Prognosis in Bladder Cancer. <i>Cancer Investigation</i> , 2021, , 1-17.	0.6	6
69	Treatment Discontinuation in Patients with Muscle-Invasive Bladder Cancer Undergoing Chemoradiation. <i>Advances in Radiation Oncology</i> , 2021, 7, 100836.	0.6	0
70	MiR-149-5p: An Important miRNA Regulated by Competing Endogenous RNAs in Diverse Human Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 743077.	1.3	7
71	SC66 inhibits the proliferation and induces apoptosis of human bladder cancer cells by targeting the AKT/β-catenin pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10684-10697.	1.6	7
72	Prognostic Value of Lymphocyte-C-Reactive Protein Ratio in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Population-Based Study. <i>Frontiers in Oncology</i> , 2021, 11, 760389.	1.3	4
73	Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1497-1506.	2.0	20
74	Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models. <i>Cancer Diagnosis &amp; Prognosis</i> , 2021, 1, 245-263.	0.3	2

#	ARTICLE	IF	CITATIONS
75	Proteomics as a Complementary Technique to Characterize Bladder Cancer. <i>Cancers</i> , 2021, 13, 5537.	1.7	4
76	Starvation induced autophagy promotes the progression of bladder cancer by LDHA mediated metabolic reprogramming. <i>Cancer Cell International</i> , 2021, 21, 597.	1.8	11
77	Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence. <i>Bioengineered</i> , 2021, 12, 11108-11125.	1.4	6
78	A Novel Assessment Model Based on Molecular Subtypes of Hypoxia-Related lncRNAs for Prognosis of Bladder Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 718991.	1.8	5
79	A Novel Immune-Gene Pair Signature Revealing the Tumor Microenvironment Features and Immunotherapy Prognosis of Muscle-Invasive Bladder Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 764184.	1.1	5
80	Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy. <i>Cancer Research and Treatment</i> , 2022, 54, 894-906.	1.3	6
81	RAF1 amplification: an exemplar of MAPK pathway activation in urothelial carcinoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	6
82	FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance. <i>Cancer Research</i> , 2022, 82, 114-129.	0.4	50
83	Curative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 678896.	1.3	6
84	A circadian rhythm-related gene signature associated with tumor immunity, cisplatin efficacy, and prognosis in bladder cancer. <i>Aging</i> , 2021, 13, .	1.4	12
85	Multi-Omics Analysis of Novel Signature for Immunotherapy Response and Tumor Microenvironment Regulation Patterns in Urothelial Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 764125.	1.8	4
86	Systematic review and meta-analysis on laparoscopic cystectomy in bladder cancer. <i>Translational Andrology and Urology</i> , 2022, 11, 67-78.	0.6	2
87	Long Noncoding RNA <i>HAND2-AS1</i> Suppresses Cell Proliferation, Migration, and Invasion of Bladder Cancer via <i>miR-17-5p</i> / <i>KLF9</i> Axis. <i>DNA and Cell Biology</i> , 2022, 41, 179-189.	0.9	5
88	Development and validation of pyroptosis-related lncRNAs prediction model for bladder cancer. <i>Bioscience Reports</i> , 2022, 42, .	1.1	2
89	Ferroptosis Mediation Patterns Reveal Novel Tool to Implicate Immunotherapy and Multi-Omics Characteristics in Bladder Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 791630.	1.8	6
90	Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2117-2126.	2.0	1
91	Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 81, 414-425.	0.9	40
92	Model Construction and Identification of Genome Instability-Associated lncRNA Signature Markers in Bladder Cancer. <i>Journal of Biosciences and Medicines</i> , 2022, 10, 46-63.	0.1	0

#	ARTICLE	IF	CITATIONS
93	Current Advances in N6-Methyladenosine Methylation Modification During Bladder Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 825109.	1.1	10
94	Bladder Cancer-Derived Exosomal KRT6B Promotes Invasion and Metastasis by Inducing EMT and Regulating the Immune Microenvironment. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
95	TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. <i>British Journal of Cancer</i> , 2022, 126, 1310-1317.	2.9	7
96	NFE2L3 promotes tumor progression and predicts a poor prognosis of bladder cancer. <i>Carcinogenesis</i> , 2022, 43, 457-468.	1.3	7
97	High expression of tight junction protein 1 as a predictive biomarker for bladder cancer grade and staging. <i>Scientific Reports</i> , 2022, 12, 1496.	1.6	4
99	TNF Family-Based Signature Predicts Prognosis, Tumor Microenvironment, and Molecular Subtypes in Bladder Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 800967.	1.8	12
100	Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway. <i>Cancer Cell International</i> , 2022, 22, 7.	1.8	14
101	Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma. <i>Oncologist</i> , 2022, 27, 432-e452.	1.9	2
102	Angioprevention of Urologic Cancers by Plant-Derived Foods. <i>Pharmaceutics</i> , 2022, 14, 256.	2.0	11
103	Clinical Efficacy and Quality of Life Assessment of Partial Cystectomy and Plasmakinetic Transurethral Resection of Tumor in Bladder Cancer Patients. <i>Cancer Management and Research</i> , 2022, Volume 14, 389-398.	0.9	1
104	A Review of Progress in the Construction and Application of Human-Derived Xenograft Models for Bladder Cancer. <i>Journal of Biosciences and Medicines</i> , 2022, 10, 27-38.	0.1	0
105	Emerging new therapeutic antibody derivatives for cancer treatment. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 39.	7.1	158
106	Circular RNAs and Drug Resistance in Genitourinary Cancers: A Literature Review. <i>Cancers</i> , 2022, 14, 866.	1.7	5
107	Bladder cancer: from a therapeutic wilderness to so many options; a guide to practice in a changing landscape. <i>Annals of Oncology</i> , 2022, 33, 242-243.	0.6	3
108	A Novel Prognostic Signature Based on Ferroptosis-Related Genes Predicts the Prognosis of Patients With Advanced Bladder Urothelial Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 726486.	1.3	6
109	An Unfolded Protein Response Related Signature Could Robustly Predict Survival Outcomes and Closely Correlate With Response to Immunotherapy and Chemotherapy in Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 780329.	1.6	5
110	CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer. <i>British Journal of Cancer</i> , 2022, 126, 1581-1588.	2.9	16
111	Occludin facilitates tumour angiogenesis in bladder cancer by regulating IL8/STAT3 through STAT4. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 2363-2376.	1.6	11

#	ARTICLE	IF	CITATIONS
112	Clinical Applications and Anticancer Effects of Antimicrobial Peptides: From Bench to Bedside. <i>Frontiers in Oncology</i> , 2022, 12, 819563.	1.3	39
113	Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers. <i>Pharmaceuticals</i> , 2022, 15, 295.	1.7	7
114	An immune-related lncRNA model for predicting prognosis, immune landscape and chemotherapeutic response in bladder cancer. <i>Scientific Reports</i> , 2022, 12, 3225.	1.6	5
115	Three-Dimensional Ultrasound Images in the Assessment of Bladder Tumor Health Monitoring under Deep Learning Algorithms. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-10.	0.7	4
116	Immunosuppressive tumor-associated macrophages expressing interleukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. , 2022, 10, e003416.		28
117	The Prognostic Role of CDK9 in Bladder Cancer. <i>Cancers</i> , 2022, 14, 1492.	1.7	7
118	Neoadjuvant Chemotherapy for Different Stages of Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis. <i>Disease Markers</i> , 2022, 2022, 1-11.	0.6	1
119	E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter. <i>Cancer Cell International</i> , 2022, 22, 109.	1.8	3
120	Gypenoside-Induced Apoptosis via the PI3K/AKT/mTOR Signaling Pathway in Bladder Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-15.	0.9	14
121	A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Muscle-Invasive Bladder Cancer Patients after Partial Cystectomy. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	3
122	External validation of Pentafecta in patients undergoing laparoscopic radical cystectomy: results from a high-volume center. <i>BMC Urology</i> , 2022, 22, 41.	0.6	2
123	SUMOylation Pattern Predicts Prognosis and Indicates Tumor Microenvironment Infiltration Characterization in Bladder Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 864156.	2.2	11
125	Solasonine Induces Apoptosis and Inhibits Proliferation of Bladder Cancer Cells by Suppressing NRP1 Expression. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	11
126	Muscle-invasive bladder cancer: pretreatment prediction of response to neoadjuvant chemotherapy with diffusion-weighted MR imaging. <i>Abdominal Radiology</i> , 2022, 47, 2148-2157.	1.0	3
127	An Immunosenescence-Related Gene Signature to Evaluate the Prognosis, Immunotherapeutic Response, and Cisplatin Sensitivity of Bladder Cancer. <i>Disease Markers</i> , 2022, 2022, 1-34.	0.6	2
128	Tenascin-C promotes bladder cancer progression and its action depends on syndecan-4 and involves NF- $\kappa$ B signaling activation. <i>BMC Cancer</i> , 2022, 22, 240.	1.1	8
129	New Directions and Challenges in Targeted Therapies of Advanced Bladder Cancer: The Role of FGFR Inhibitors. <i>Cancers</i> , 2022, 14, 1416.	1.7	7
130	Overexpression of Her-2 in Biopsy-Proven Urothelial Carcinoma Patients From Pakistan. <i>Cureus</i> , 2022, 14, e23739.	0.2	0



#	ARTICLE	IF	CITATIONS
131	Surface-Enhanced Raman Spectroscopy of Pretreated Plasma Samples Predicts Disease Recurrence in Muscle-Invasive Bladder Cancer Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 1635-1646.	3.3	4
132	Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer. <i>Human Genomics</i> , 2021, 15, 73.	1.4	8
133	TRIM38 triggers the ubiquitination and degradation of glucose transporter type 1 (GLUT1) to restrict tumor progression in bladder cancer. <i>Journal of Translational Medicine</i> , 2021, 19, 508.	1.8	18
134	Auranofin induces urothelial carcinoma cell death via reactive oxygen species production and synergy with cisplatin.. <i>Oncology Letters</i> , 2022, 23, 61.	0.8	2
135	Pyroptosis-Related Signature Predicts Prognosis and Immunotherapy Efficacy in Muscle-Invasive Bladder Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 782982.	2.2	19
136	The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 344.e1-344.e9.	0.8	5
137	G-Protein Subunit Gamma 4 as a Potential Biomarker for Predicting the Response of Chemotherapy and Immunotherapy in Bladder Cancer. <i>Genes</i> , 2022, 13, 693.	1.0	4
138	Disease Management of Clinical Complete Responders to Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer: A Review of Literature. <i>Frontiers in Oncology</i> , 2022, 12, 816444.	1.3	7
139	In Silico Establishment and Validation of Novel Lipid Metabolism-Related Gene Signature in Bladder Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-20.	1.9	4
140	Effects of radical cystectomy combined with GC chemotherapy in the treatment of invasive bladder cancer and its influence on the incidence of adverse reactions.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 13845-13853.	0.0	0
141	Patient-derived organoids as a model for tumor research. <i>Progress in Molecular Biology and Translational Science</i> , 2022, , 259-326.	0.9	2
142	Homologous Recombination Related Signatures Predict Prognosis and Immunotherapy Response in Metastatic Urothelial Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 875128.	1.1	4
143	Pyroptosis-Related Patterns Predict Tumor Immune Landscape and Immunotherapy Response in Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 815290.	1.6	2
144	Development, regeneration and tumorigenesis of the urothelium. <i>Development (Cambridge)</i> , 2022, 149, .	1.2	6
145	M2 Tumor Associate Macrophage- (TAM-) Derived lncRNA HISLA Promotes EMT Potential in Bladder Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-13.	0.6	0
146	Development of a MRI-Based Radiomics Nomogram for Prediction of Response of Patients With Muscle-Invasive Bladder Cancer to Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	9
147	Anti-cancer effect of LINC00478 in bladder cancer correlates with KDM1A-dependent MMP9 demethylation. <i>Cell Death Discovery</i> , 2022, 8, 242.	2.0	6
148	Immune Microenvironment Terms Signature Robustly Predicts the Prognosis and Immunotherapy Response in Bladder Cancer Based on Large Population Cohorts. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	0

#	ARTICLE	IF	CITATIONS
149	Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma. <i>Cancer Cell International</i> , 2022, 22, 186.	1.8	4
150	circSPECC1 promotes bladder cancer progression via regulating miR-136-5p/GNAS axis. <i>Pathology Research and Practice</i> , 2022, 234, 153914.	1.0	4
151	lncRNA PGM5-AS1 inhibits the progression of bladder cancer by regulating miR-587/SLIT3 axis. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2022, , .	0.4	0
152	Deep Learning-Based CT Imaging to Evaluate the Therapeutic Effects of Acupuncture and Moxibustion Therapy on Knee Osteoarthritis. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-9.	0.7	3
153	Effective Radiosensitization of Bladder Cancer Cells by Pharmacological Inhibition of DNA-PK and ATR. <i>Biomedicines</i> , 2022, 10, 1277.	1.4	3
154	Identification of hub genes associated with bladder cancer using bioinformatic analyses. <i>Translational Cancer Research</i> , 2022, 11, 1330-1343.	0.4	3
155	Molecular Oncology of Bladder Cancer from Inception to Modern Perspective. <i>Cancers</i> , 2022, 14, 2578.	1.7	9
156	Nanomedicine for urologic cancers: diagnosis and management. <i>Seminars in Cancer Biology</i> , 2022, 86, 463-475.	4.3	3
158	<sc>RITA1</sc> drives the growth of bladder cancer cells by recruiting <sc>TRIM25</sc> to facilitate the proteasomal degradation of <sc>RBPJ</sc>. <i>Cancer Science</i> , 2022, 113, 3071-3084.	1.7	5
159	Identification of Novel Tumor Antigens and the Immune Landscapes of Bladder Cancer Patients for mRNA Vaccine Development. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
160	Intelligent diagnosis of bladder cancer with limited MRI data. <i>Journal of Ambient Intelligence and Humanized Computing</i> , 0, , .	3.3	0
161	Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-10.	0.5	1
162	Prognosis Analysis and Perioperative Research of Elderly Patients with Non-Muscle-Invasive Bladder Cancer under Computed Tomography Image of Three-Dimensional Reconstruction Algorithm. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-9.	0.4	0
163	Discovery of Notch Pathway-Related Genes for Predicting Prognosis and Tumor Microenvironment Status in Bladder Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
164	Comprehensive Characterization of Necroptosis-Related lncRNAs in Bladder Cancer Identifies a Novel Signature for Prognosis Prediction. <i>Disease Markers</i> , 2022, 2022, 1-30.	0.6	5
165	Highly Expressed <i>LINC00958</i> Modulates the Growth and Epithelial-Mesenchymal Transition of Bladder Cancer Cells Through <i>SAPK/JNK</i> Signaling Pathway. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 0, , .	0.7	2
166	Computational Analysis Identifies Novel Biomarkers for High-Risk Bladder Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7057.	1.8	1
167	RAC3 Inhibition Induces Autophagy to Impair Metastasis in Bladder Cancer Cells via the PI3K/AKT/mTOR Pathway. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5

#	ARTICLE	IF	CITATIONS
168	Advances in Diagnosis and Therapy for Bladder Cancer. <i>Cancers</i> , 2022, 14, 3181.	1.7	16
169	High-throughput screening identifies stevioside as a potent agent to induce apoptosis in bladder cancer cells. <i>Biochemical Pharmacology</i> , 2022, 203, 115166.	2.0	4
170	Bladder cancer-derived exosomal KRT6B promotes invasion and metastasis by inducing EMT and regulating the immune microenvironment. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	17
171	Variation of Anxiety and Depression During a 3-Year Period as Well as Their Risk Factors and Prognostic Value in Postoperative Bladder Cancer Patients. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	0
172	A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
174	Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer. <i>Journal of Big Data</i> , 2022, 9, .	6.9	12
175	NEAT1/MALAT1/XIST/PKD-Hsa-Mir-101-3p-DLGAP5 Axis as a Novel Diagnostic and Prognostic Biomarker Associated With Immune Cell Infiltration in Bladder Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
176	CNN1 Represses Bladder Cancer Progression and Metabolic Reprogramming by Modulating HIF-1 $\alpha$ Signaling Pathway. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
177	Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	5
178	Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
179	Network Pharmacology Research and Dual-omic Analyses Reveal the Molecular Mechanism of Natural Product Nodosin Inhibiting Muscle-Invasive Bladder Cancer <i>in Vitro</i> and <i>in Vivo</i> . <i>Journal of Natural Products</i> , 2022, 85, 2006-2017.	1.5	4
180	Biodegradable ring-shaped implantable device for intravesical therapy of bladder disorders. <i>Biomaterials</i> , 2022, 288, 121703.	5.7	6
181	Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients. <i>British Journal of Cancer</i> , 2022, 127, 1718-1725.	2.9	1
182	A novel molecular subtypes and risk model based on inflammatory response-related lncRNAs for bladder cancer. <i>Hereditas</i> , 2022, 159, .	0.5	0
183	Prognostic value of preoperative platelet-related parameters and plasma fibrinogen in patients with non-muscle invasive bladder cancer after transurethral resection of bladder tumor. <i>Future Oncology</i> , 2022, 18, 2933-2942.	1.1	3
184	Comprehensive analysis of the endoplasmic reticulum stress-related long non-coding RNA in bladder cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
186	Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1380-1391.	3.0	4
187	Preoperative Nutritional Risk Assessment for Predicting Complications after Radical Cystectomy plus Urinary Diversion for Bladder Cancer. <i>Emergency Medicine International</i> , 2022, 2022, 1-6.	0.3	3

#	ARTICLE	IF	CITATIONS
188	Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1674-1688.	1.9	5
189	Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	86
190	Deubiquitinase OTUD5 modulates mTORC1 signaling to promote bladder cancer progression. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	10
191	Immunotherapy for Bladder Cancer: Latest Advances and Ongoing Clinical Trials. <i>Immunological Investigations</i> , 2022, 51, 2226-2251.	1.0	14
192	Hsa_circ_0003221 facilitates the malignant development of bladder cancer cells via resulting in the upregulation of DHCR24 by targeting miR-892b. <i>Investigative and Clinical Urology</i> , 2022, 63, 577.	1.0	3
193	High-Grade Urothelial Carcinoma with Squamous Differentiation and Favourable Response to Immunotherapy – a Case Report. <i>Journal of Medical &amp; Radiation Oncology</i> , 2022, 2, 57-61.	0.0	0
194	Dynamic alteration and prognostic significance of tumor-associated CD68 <sup>+</sup> and CD68 <sup>+</sup> PD-L1 <sup>+</sup> macrophages in muscle-invasive bladder cancer treated with neoadjuvant chemotherapy. <i>Cancer Medicine</i> , 0, , .	1.3	1
195	Identification and verification of the pyroptosis-related prognostic signature and its associated regulatory axis in bladder cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
196	Induction of RAC1 protein translation and MKK7/JNK-dependent autophagy through dicer/miR-145/SOX2/miR-365a axis contributes to isorhapontigenin (ISO) inhibition of human bladder cancer invasion. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	6
197	NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. <i>Cancer Cell</i> , 2022, 40, 1027-1043.e9.	7.7	34
198	An enhancer RNA-based risk model for prediction of bladder cancer prognosis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
199	Circular RNA-regulated autophagy is involved in cancer progression. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	4
200	Urine exosomes as biomarkers in bladder cancer diagnosis and prognosis: From functional roles to clinical significance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
201	Immune status for monitoring and treatment of bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
202	State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer. <i>Biosensors</i> , 2022, 12, 796.	2.3	11
203	Gasdermin D: A potential mediator and prognostic marker of bladder cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	3
204	Analysis of the Relationship between Bladder Cancer Gene Mutation and Clinical Prognosis by High-Throughput Sequencing. <i>Laboratory Medicine</i> , 2023, 54, 142-152.	0.8	1
205	Comprehensive analyses of a tumor-infiltrating lymphocytes-related gene signature regarding the prognosis and immunologic features for immunotherapy in bladder cancer on the basis of WGCNA. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4

#	ARTICLE	IF	CITATIONS
206	Values of OAS gene family in the expression signature, immune cell infiltration and prognosis of human bladder cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
207	Comprehensive analysis of cuproptosis-related long noncoding RNA immune infiltration and prediction of prognosis in patients with bladder cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	11
208	STAT3 and Its Pathwaysâ€™™ Dysregulationâ€™™ Underestimated Role in Urological Tumors. <i>Cells</i> , 2022, 11, 3024.	1.8	8
209	Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
210	Role of the JNK Pathway in Bladder Cancer. <i>OncoTargets and Therapy</i> , 0, Volume 15, 963-971.	1.0	4
211	Characterization of the Lipid Metabolism in Bladder Cancer to Guide Clinical Therapy. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	4
212	HOXA1 promotes proliferation and metastasis of bladder cancer by enhancing SMAD3 transcription. <i>Pathology Research and Practice</i> , 2022, 239, 154141.	1.0	7
215	EPDR1 levels and tumor budding predict and affect the prognosis of bladder carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
216	Immune-related gene risk score predicting the effect of immunotherapy and prognosis in bladder cancer patients. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
217	Revealing prognostic and tumor microenvironment characteristics of cuproptosis in bladder cancer by genomic analysis. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
218	A novel prognostic model based on three integrin subunit genes-related signature for bladder cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
220	TFAP2C Knockdown Sensitizes Bladder Cancer Cells to Cisplatin Treatment via Regulation of EGFR and NF-Î²B. <i>Cancers</i> , 2022, 14, 4809.	1.7	6
221	The tumor microenvironment and prognostic role of autophagy- and immune-related genes in bladder cancer. <i>Cancer Biomarkers</i> , 2022, 35, 293-303.	0.8	3
222	Systematical analysis of ferroptosis regulators and identification of GCLM as a tumor promotor and immunological biomarker in bladder cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
224	Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
225	<sc>LncRNA SNHG3</sc> enhances <sc>BMI1 mRNA</sc> stability by binding and regulating <sc>câ€™MYC</sc>: Implications for the carcinogenic role of <sc>SNHG3</sc> in bladder cancer. <i>Cancer Medicine</i> , 2023, 12, 5718-5735.	1.3	6
226	A Novel Risk Model for lncRNAs Associated with Oxidative Stress Predicts Prognosis of Bladder Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	0.6	4
227	LINC00958 Inhibits Autophagy of Bladder Cancer Cells via Sponge Adsorption of miR-625-5p to Promote Tumor Angiogenesis and Oxidative Stress. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-14.	1.9	5

#	ARTICLE	IF	CITATIONS
228	Prognostic significance and identification of basement membrane-associated lncRNA in bladder cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
229	Circ_0002099 is a novel molecular therapeutic target for bladder cancer. <i>Drug Development Research</i> , 2022, 83, 1890-1905.	1.4	4
230	Analysis of prognostic oncogene filaggrin (FLG) wild-type subtype and its implications for immune checkpoint blockade therapy in bladder urothelial carcinoma. <i>Translational Andrology and Urology</i> , 2022, 11, 1419-1432.	0.6	1
231	Identification of adenylate cyclase 2 methylation in bladder cancer with implications for prognosis and immunosuppressive microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
232	Distinct immune and inflammatory response patterns contribute to the identification of poor prognosis and advanced clinical characters in bladder cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
233	Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, .	0.4	1
235	Protodioscin inhibits bladder cancer cell migration and growth, and promotes apoptosis through activating JNK and p38 signaling pathways. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113929.	2.5	10
236	Effect of long noncoding RNA NONHSAT070806 on the apoptosis, proliferation, migration, invasion and tumorigenesis of bladder cancer. <i>Translational Andrology and Urology</i> , 2021, .	0.6	0
237	Integrative Bioinformatics Analysis of Transcriptomic Data Reveals Hub Genes as Diagnostic Biomarkers for Non-Muscle vs. Muscle Invasive Bladder Cancer. , 2022, , .		0
238	The global research of bladder cancer immunotherapy from 2012 to 2021: A bibliometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
239	Identification and validation of novel biomarkers affecting bladder cancer immunotherapy via machine learning and its association with M2 macrophages. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
240	Impact of SOX2 function and regulation on therapy resistance in bladder cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
241	Systems Drug Design for Muscle Invasive Bladder Cancer and Advanced Bladder Cancer by Genome-Wide Microarray Data and Deep Learning Method with Drug Design Specifications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13869.	1.8	4
242	Risk and prognosis of secondary malignant neoplasms after radiation therapy for bladder cancer: A large population-based cohort study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
245	Primary lung cancer treatable with radical resection after complete remission with pembrolizumab therapy following gemcitabine and carboplatin chemotherapy for multiple metastases of bladder cancer. <i>IJU Case Reports</i> , 2023, 6, 85-88.	0.1	1
246	A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
247	Single cell sequencing reveals that CD39 inhibition mediates changes to the tumor microenvironment. <i>Nature Communications</i> , 2022, 13, .	5.8	13
248	Development and validation of a novel model for predicting the survival of bladder cancer based on ferroptosis-related genes. <i>Aging</i> , 2022, 14, 9037-9055.	1.4	5

#	ARTICLE	IF	CITATIONS
249	Downregulation of CBX7 induced by EZH2 upregulates FGFR3 expression to reduce sensitivity to cisplatin in bladder cancer. <i>British Journal of Cancer</i> , 2023, 128, 232-244.	2.9	4
250	PXDNL activates the motility of urothelial bladder carcinoma cells through the Wnt/ $\beta$ 2-catenin pathway and has a prognostic value. <i>Life Sciences</i> , 2023, 312, 121270.	2.0	1
251	The oncogenic role of TFAP2A in bladder urothelial carcinoma via a novel long noncoding RNA TPRG1-AS1/DNMT3A/CRTAC1 axis. <i>Cellular Signalling</i> , 2023, 102, 110527.	1.7	9
252	lncRNA-mediated ceRNA network in bladder cancer. <i>Non-coding RNA Research</i> , 2023, 8, 135-145.	2.4	11
253	Frontiers in Non-metastatic, Muscle-invasive Bladder Cancer. <i>Touch Reviews in Oncology &amp; Haematology</i> , 2022, 18, 113.	0.1	0
254	The prognosis of bladder cancer is affected by fatty acid metabolism, inflammation, and hypoxia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
255	The comparison between contrast-enhanced ultrasound and contrast-enhanced magnetic resonance imaging in diagnosing bladder urothelial carcinoma. <i>International Urology and Nephrology</i> , 2023, 55, 1073-1079.	0.6	2
256	Accurate Diagnosis and Survival Prediction of Bladder Cancer Using Deep Learning on Histological Slides. <i>Cancers</i> , 2022, 14, 5807.	1.7	5
257	A reporting quality evaluation of the clinical practice guidelines for bladder cancer based on the RIGHT checklist. <i>Translational Andrology and Urology</i> , 2022, 11, 1586-1597.	0.6	0
258	The status of bladder cancer research worldwide, a bibliometric review and recommendations. <i>Arab Journal of Urology Arab Association of Urology</i> , 0, , 1-9.	0.7	1
259	Quantitative Assessment of Tumor-Infiltrating Lymphocytes Using Machine Learning Predicts Survival in Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 7081.	1.0	4
260	MiRNA-139-3p inhibits malignant progression in urothelial carcinoma of the bladder via targeting KIF18B and inactivating Wnt/beta-catenin pathway. <i>Pharmacogenetics and Genomics</i> , 2023, 33, 1-9.	0.7	2
261	A novel in vitro prognostic model of bladder cancer based on urine-derived living tumor cells. <i>Genes and Diseases</i> , 2022, , .	1.5	1
262	Hispolon Methyl Ether, a Hispolon Analog, Suppresses the SRC/STAT3/Survivin Signaling Axis to Induce Cytotoxicity in Human Urinary Bladder Transitional Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2023, 24, 138.	1.8	3
264	Daurisolone Inhibiting Tumor Angiogenesis and Epithelial-Mesenchymal Transition in Bladder Cancer by Mediating HAKAI Protein Stability. <i>Iranian Journal of Pharmaceutical Research</i> , 2022, 21, .	0.3	1
265	Prognostic nutritional index of early post- pembrolizumab therapy predicts long-term survival in patients with advanced urothelial carcinoma. <i>Oncology Letters</i> , 2022, 25, .	0.8	2
266	A risk model based on pyroptosis subtypes predicts tumor immune microenvironment and guides chemotherapy and immunotherapy in bladder cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
267	Starvation-induced long non-coding RNAs are significant for prognosis evaluation of bladder cancer. <i>Ageing</i> , 0, , .	1.4	0

#	ARTICLE	IF	CITATIONS
268	Constructing and validating nomograms to predict risk and prognostic factors of distant metastasis in urothelial bladder cancer patients: a population-based retrospective study. <i>BMC Urology</i> , 2022, 22, .	0.6	3
269	Immunohistochemical Algorithm for the Classification of Muscle-Invasive Urinary Bladder Carcinoma with Lymph Node Metastasis: An Institutional Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 7430.	1.0	0
270	Construction and experimental validation of a B cell senescence-related gene signature to evaluate prognosis and immunotherapeutic sensitivity in bladder cancer. <i>Functional and Integrative Genomics</i> , 2023, 23, .	1.4	4
271	RGD peptide modified platinum nanozyme Co-loaded glutathione-responsive prodrug nanoparticles for enhanced chemo-photodynamic bladder cancer therapy. <i>Biomaterials</i> , 2023, 293, 121975.	5.7	25
272	Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation. <i>Molecular Medicine</i> , 2023, 29, .	1.9	2
273	BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity. <i>Advanced Science</i> , 2023, 10, .	5.6	23
274	An IFN- $\gamma$ -related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
275	Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer. <i>Cancers</i> , 2023, 15, 566.	1.7	1
276	Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin $\alpha 5/\beta 1$ -FAK/Src axis: A novel strategy for drug application. <i>Pharmacological Research</i> , 2023, 188, 106654.	3.1	8
277	Bioinformatics analysis of prognosis and immune microenvironment of immunological cell death-related gemcitabine-resistance genes in bladder cancer. <i>Translational Andrology and Urology</i> , 2022, 11, 1715-1728.	0.6	2
278	An angiogenesis-related lncRNA signature for the prognostic prediction of patients with bladder cancer and LINC02321 promotes bladder cancer progression via the VEGFA signaling pathway. <i>Molecular Medicine Reports</i> , 2022, 27, .	1.1	5
279	Identification of platinum resistance-related gene signature for prognosis and immune analysis in bladder cancer. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	2
280	Stelletin B Induces Cell Death in Bladder Cancer Via Activating the Autophagy/DAPK2/Apoptosis Signaling Cascade. <i>Marine Drugs</i> , 2023, 21, 73.	2.2	6
281	Mapping the tumor microenvironment in bladder cancer and exploring the prognostic genes by single-cell RNA sequencing. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
282	Mendelian randomization investigation identified the causal relationship between body fat indexes and the risk of bladder cancer. <i>PeerJ</i> , 0, 11, e14739.	0.9	1
283	Construction and validation of a bladder cancer risk model based on autophagy-related genes. <i>Functional and Integrative Genomics</i> , 2023, 23, .	1.4	1
284	Time Matters: Importance of Circadian Rhythms, Disruption, and Chronotherapy in Urologic Malignancies. <i>Urology</i> , 2023, 175, 6-12.	0.5	1
285	Impact of tissue inhibitor of metalloproteinases-3 genetic variants on clinicopathological characteristics of urothelial cell carcinoma. <i>Journal of Cancer</i> , 2023, 14, 360-366.	1.2	0



#	ARTICLE	IF	CITATIONS
286	A prognostic cuproptosis-related lncRNA predictive signature for bladder cancer patients. <i>Human Cell</i> , 0, .	1.2	0
287	Development and Validation of Nomograms Predicting the 5- and 8-Year Overall and Cancer-Specific Survival of Bladder Cancer Patients Based on SEER Program. <i>Journal of Clinical Medicine</i> , 2023, 12, 1314.	1.0	2
288	HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1/PKM2 pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	13
289	Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis. <i>Anti-Cancer Drugs</i> , 2023, 34, 473-478.	0.7	0
290	HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2309-2318.	2.0	9
291	KRT13-expressing epithelial cell population predicts better response to chemotherapy and immunotherapy in bladder cancer: Comprehensive evidences based on BCa database. <i>Computers in Biology and Medicine</i> , 2023, 158, 106795.	3.9	0
292	TJP1 promotes vascular mimicry in bladder cancer by facilitating VEGFA expression and transcriptional activity through TWIST1. <i>Translational Oncology</i> , 2023, 32, 101666.	1.7	1
293	The c-MYC transcription factor conduces to resistance to cisplatin by regulating MMS19 in bladder cancer cells. <i>Tissue and Cell</i> , 2023, 82, 102096.	1.0	0
294	Translational albumin nanocarrier caging photosensitizer for efficient cancer photodynamic therapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 11, .	2.0	2
295	Identification and validation of a novel prognostic model based on platinum resistance-related genes in bladder cancer. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2023, 49, 61-88.	0.7	2
297	Ligustilide induces apoptosis and reduces proliferation in human bladder cancer cells by $\text{NF-}\kappa\text{B}$ and mitochondria pathway. <i>Chemical Biology and Drug Design</i> , 2023, 101, 1252-1261.	1.5	5
299	Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives. <i>Journal of Clinical Medicine</i> , 2023, 12, 1446.	1.0	7
300	Metabolic Modulation of Intracellular Ammonia via Intravesical Instillation of Nanopporter-Encased Hydrogel Eradicates Bladder Carcinoma. <i>Advanced Science</i> , 2023, 10, .	5.6	4
301	Cytoskeleton regulator RNA expression on cancer-associated fibroblasts is associated with prognosis and immunotherapy response in bladder cancer. <i>Heliyon</i> , 2023, 9, e13707.	1.4	0
302	Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2057-2065.	2.0	1
303	Trends and risk factors of global incidence, mortality, and disability of genitourinary cancers from 1990 to 2019: Systematic analysis for the Global Burden of Disease Study 2019. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	8
304	Prognostic nomogram for estimating survival in patients with resected muscle-invasive bladder cancer receiving chemotherapy. <i>Frontiers in Surgery</i> , 0, 10, .	0.6	1
305	Clinical Significance and Tumor Microenvironment Characterization of a Novel Immune-Related Gene Signature in Bladder Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 1892.	1.0	1

#	ARTICLE	IF	CITATIONS
306	Ubiquitin-Specific Proteases as Potential Therapeutic Targets in Bladder Cancerâ€”In Vitro Evaluation of Degrasyn and PR-619 Activity Using Human and Canine Models. <i>Biomedicines</i> , 2023, 11, 759.	1.4	1
307	Regulation of CD8+ T cells infiltration and immunotherapy by circMGA/HNRNPL complex in bladder cancer. <i>Oncogene</i> , 2023, 42, 1247-1262.	2.6	4
308	Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages. <i>Heliyon</i> , 2023, 9, e14272.	1.4	3
309	PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression. <i>Cell and Bioscience</i> , 2023, 13, .	2.1	5
310	The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
311	Differential Occupancy and Regulatory Interactions of KDM6A in Bladder Cell Lines. <i>Cells</i> , 2023, 12, 836.	1.8	1
312	HSPA5 Promotes the Proliferation, Metastasis and Regulates Ferroptosis of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5144.	1.8	7
313	Comprehensive analysis reveals the value of the expression of chromobox family members for bladder urothelial carcinoma prognosis. <i>Oncology Letters</i> , 2023, 25, .	0.8	2
314	Anlotinib Enhances the Therapeutic Effect of Bladder Cancer with GSDMB Expression: Analyzed from TCGA Bladder Cancer Database & Mouse Bladder Cancer Cell Line. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 16, 219-228.	0.4	0
315	Cancer-Associated Fibroblastâ€™Derived miR-146a-5p Generates a Niche That Promotes Bladder Cancer Stemness and Chemoresistance. <i>Cancer Research</i> , 2023, 83, 1611-1627.	0.4	21
316	An innovative risk index based on neutrophils and macrophages can effectively predict prognosis and immunotherapy response in patients with muscle-invasive bladder cancer. <i>Translational Cancer Research</i> , 2023, 12, 536-549.	0.4	0
317	METTL3/YTHDF2 m6A axis promotes the malignant progression of bladder cancer by epigenetically suppressing RRAS. <i>Oncology Reports</i> , 2023, 49, .	1.2	3
318	The emerging roles of lysine-specific demethylase 4A in cancer: Implications in tumorigenesis and therapeutic opportunities. <i>Genes and Diseases</i> , 2024, 11, 645-663.	1.5	2
320	Machine learning-based identification of tumor-infiltrating immune cell-associated model with appealing implications in improving prognosis and immunotherapy response in bladder cancer patients. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
321	Selective Cellular Uptake and Cytotoxicity of Curcumin-encapsulated SPC and HSPC Liposome Nanoparticles on Human Bladder Cancer Cells. <i>Current Pharmaceutical Design</i> , 2023, 29, 1046-1058.	0.9	4
322	Identification of Essential Genes and Drug Discovery in Bladder Cancer and Inflammatory Bowel Disease via Text Mining and Bioinformatics Analysis. <i>Current Computer-Aided Drug Design</i> , 2024, 20, 359-366.	0.8	1
323	A comprehensive analysis of immunogenic cell death and its key gene HSP90AA1 in bladder cancer. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	0
324	Raman Spectroscopic Imaging of Human Bladder Resectates towards Intraoperative Cancer Assessment. <i>Cancers</i> , 2023, 15, 2162.	1.7	2

#	ARTICLE	IF	CITATIONS
325	Potential mechanisms of osthole against bladder cancer cells based on network pharmacology, molecular docking, and experimental validation. <i>BMC Complementary Medicine and Therapies</i> , 2023, 23, .	1.2	2
327	P2X1 and P2X7 Receptor Overexpression Is a Negative Predictor of Survival in Muscle-Invasive Bladder Cancer. <i>Cancers</i> , 2023, 15, 2321.	1.7	3
371	Application of nanotechnology in bladder cancer diagnosis and therapeutic drug delivery. <i>Journal of Materials Chemistry B</i> , 2023, 11, 8368-8386.	2.9	1